Advocates in Canberra have called on the government to urgently subsidise new, advanced treatments for hepatitis C, saying each month they delay about 50 people die from the condition.
The Pharmaceutical Benefits Advisory Committee recommended on April 24 that three new antiviral medications, designed to treat hepatitis C, be considered for addition to the Pharmaceutical Benefits Scheme.
Canberra Alliance for Harm Minimisation and Advocacy manager Sione Crawford, who lives with hepatitis C, said the difference between the new and old drugs was like "night and day".
Read more...
Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.
Alan Franciscus
Editor-in-Chief
HCV Advocate
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment